



## ***Jeffrey C. Thacker***

**PARTNER**

**San Diego**

P +1 858 436 8064

**Silicon Valley**

P +1 650 321 2400

Jeff is a partner in our San Diego office.

Jeff practices corporate and securities law, representing both public and private venture-backed companies. He has deep experience advising life science and technology companies in a variety of transactions, including IPOs and other public offerings, venture financings, mergers and acquisitions, and strategic collaboration and licensing transactions. He also has expertise in SEC reporting and corporate governance matters.

Jeff's representation of public companies includes Anterix, Natera, Tricida, MediciNova, Boingo Wireless, Organovo and Pure Biosciences. He also represented CareFusion until its sale to BD for \$12.2 billion, Life Technologies until its sale to Thermo Fisher for \$13.6 billion, P.F. Chang's until its sale for \$1.1 billion, and The Active Networks until its sale for \$1.0 billion.

## Credentials

### EDUCATION

- University of California, Berkeley, School of Law, J.D.
- Brigham Young University, B.S., Civil Engineering

### BAR ADMISSIONS

- California

### ACHIEVEMENTS

- Jeff was selected for inclusion in *Best Lawyers in America* in Corporate Governance Law (since 2016)

### CLERKSHIPS

- Judge Ruth V. McGregor, Arizona Court of Appeals

## Focus Areas

Corporate Governance & Strategy

Fund Investments in Companies

Initial Public Offerings (IPOs) & Direct Listings

Life Sciences

Mergers & Acquisitions

Public Companies/Public Offerings

Seed, Venture and Growth Financings

### WEBINAR

## What to Know About Crossover Rounds as a Late-Stage Private Company

Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of an IPO Summit series of workshops. The panel provided an overview of the benefits of raising capital from crossover funds from both the company and the investor perspective, as well as discussed practical considerations when choosing investors for any crossover

## Related News & Insights

### FIRM NEWS

Gunderson Dettmer Wins China Business Law Journal's 2024 "Deals of the Year"

### CLIENT NEWS

Vignette Bio Announces its Merger with Candid Therapeutics

### FIRM NEWS

Best Lawyers Recognizes 29 Gunderson Dettmer Attorneys in the 2025 Best Lawyers in America Guide

### CLIENT NEWS

Gunderson Dettmer Client JenaValve Enters Agreement to be Acquired by Edwards Lifesciences

### CLIENT NEWS

Element Biosciences Announces \$277M Series D

### CLIENT NEWS

AI Biotech Xaira Therapeutics Emerges from Stealth With \$1B in Funding

### CLIENT NEWS

Inc 7th Annual Female Founders 250 List Recognizes Individuals From 5 Gunderson Dettmer Clients

### CLIENT NEWS

Archetype AI Announces \$13M Seed Led by Venrock

### CLIENT NEWS

Contineum Therapeutics Announces Initial Public Offering

### CLIENT NEWS

Cell-Free DNA Testing Company Natera Announces \$250M Follow-On Offering

## Offering

### FIRM NEWS

Best Lawyers Recognizes 25 Gunderson Dettmer Attorneys in the 2024 Best Lawyers in America Guide

### EVENTS

Webinar: What to Know About Crossover Funds as a Late-Stage Company

### CLIENT NEWS

Pipeline Therapeutics Enters into Global License and Development Agreement with Janssen